55/100 · Moderate
Manufactured by Eli Lilly and Company
Teriparatide Adverse Events: Common Mild Reactions with Some Serious Concerns
227,333 FDA adverse event reports analyzed
Last updated: 2026-05-12
TERIPARATIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Eli Lilly and Company. Based on analysis of 227,333 FDA adverse event reports, TERIPARATIDE has a safety score of 55 out of 100. This moderate score indicates a notable volume of adverse event reports that patients and providers should be aware of. The most commonly reported adverse reactions for TERIPARATIDE include NAUSEA, ARTHRALGIA, PAIN IN EXTREMITY, DIZZINESS, FALL. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for TERIPARATIDE.
Teriparatide has a safety concern score of 55 out of 100, placing it in the elevated concern category based on analysis of FDA adverse event data. The FDA has received approximately 227,333 adverse event reports for this medication, which is primarily manufactured by Eli Lilly And Company.
The most commonly reported adverse events include Nausea, Arthralgia, Pain In Extremity. Of classified reports, 37.0% were designated as serious by the FDA, meaning they involved hospitalization, disability, or other significant medical outcomes. The most common reactions are nausea, arthralgia, and pain in extremity, indicating a high incidence of musculoskeletal discomfort.
Serious adverse events, such as falls and death, are reported but at a lower rate compared to non-serious events. Injection site reactions are frequent, highlighting the importance of proper administration.
Patients taking Teriparatide should monitor for the commonly reported side effects and contact their healthcare provider if they experience any unusual symptoms. Teriparatide can cause injection site reactions, and patients should be monitored for signs of hypercalcemia and other serious adverse events. This analysis is based on voluntary FDA adverse event reports and should not replace professional medical advice.
Teriparatide received a safety concern score of 55/100 (elevated concern). This is based on a 37.0% serious event ratio across 111,255 classified reports. The score accounts for 227,333 total adverse event reports and 100 distinct reaction types. This elevated score indicates a notable proportion of serious adverse events and warrants careful monitoring.
Adverse event reports by sex: Female: 99,358, Male: 10,240, Unknown: 40. The most frequently reported age groups are age 75 (2,734 reports), age 76 (2,047 reports), age 77 (2,033 reports). These demographics reflect reporting patterns and may not represent the full patient population.
Out of 111,255 classified reports for TERIPARATIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
Teriparatide can cause injection site reactions, and patients should be monitored for signs of hypercalcemia and other serious adverse events.
If you are taking Teriparatide, here are important things to know. The most commonly reported side effects include nausea, arthralgia, pain in extremity, dizziness, fall. While many of these may be mild and temporary, you should contact your healthcare provider if any symptoms are severe or persistent. Patients should report any unusual symptoms to their healthcare provider immediately. Proper administration techniques should be followed to minimize injection site reactions. If you experience a serious adverse reaction, seek emergency medical attention immediately or call 911. You can report side effects to the FDA's MedWatch program at 1-800-FDA-1088.
The FDA continues to monitor teriparatide for safety, and updates will be provided as necessary based on ongoing reviews.
The FDA has received approximately 227,333 adverse event reports associated with Teriparatide. These reports come from healthcare professionals, consumers, and manufacturers through the FDA Adverse Event Reporting System (FAERS). Note that the number of reports does not directly indicate the frequency of side effects, as adverse events are voluntarily reported and may be underrepresented.
The most frequently reported adverse events for Teriparatide include Nausea, Arthralgia, Pain In Extremity, Dizziness, Fall. By volume, the top reported reactions are: Nausea (8,955 reports), Arthralgia (8,661 reports), Pain In Extremity (8,342 reports). These figures reflect FDA adverse event reports and may not represent the true incidence rate of these side effects in all patients taking Teriparatide.
Out of 111,255 classified reports, 41,183 (37.0%) were classified as serious and 70,072 as non-serious. The FDA classifies an event as "serious" if it results in death, hospitalization, disability, or other medically significant outcomes. A higher serious-event ratio warrants closer attention but does not necessarily mean the drug is unsafe.
Adverse event reports for Teriparatide break down by patient sex as follows: Female: 99,358, Male: 10,240, Unknown: 40. This distribution reflects reporting patterns rather than actual risk differences between groups. Reporting rates can be influenced by prescribing patterns, disease demographics, and reporting behavior.
The most frequently reported age groups for Teriparatide adverse events are: age 75: 2,734 reports, age 76: 2,047 reports, age 77: 2,033 reports, age 78: 1,990 reports, age 79: 1,964 reports. Age-related reporting patterns can reflect both the demographics of the patient population and potential age-related susceptibility to certain side effects.
The primary manufacturer associated with Teriparatide adverse event reports is Eli Lilly And Company. Multiple manufacturers may produce generic versions of this drug. The manufacturer listed reflects the most frequently reported brand in FDA adverse event data.
Beyond the most common reactions, other reported adverse events for Teriparatide include: Pain, Fatigue, Back Pain, Muscle Spasms, Malaise. Less common side effects can still be clinically significant. Patients should report any unusual symptoms to their healthcare provider.
You can report adverse events from Teriparatide to the FDA through their MedWatch program at www.fda.gov/medwatch, by calling 1-800-FDA-1088, or by completing Form FDA 3500. Healthcare professionals, consumers, and manufacturers can all submit reports. Reporting helps the FDA monitor drug safety after approval.
Teriparatide has a safety concern score of 55 out of 100 (elevated concern). This score is calculated from the ratio of serious to non-serious adverse events, the diversity of reported reactions, and the overall volume of reports relative to usage. The most common reactions are nausea, arthralgia, and pain in extremity, indicating a high incidence of musculoskeletal discomfort.
Key safety signals identified in Teriparatide's adverse event data include: Falls and fractures are reported, which could be related to the drug's mechanism of action on bone density.. Increased blood calcium levels are noted, suggesting a risk of hypercalcemia.. Death reports are present, though not frequent, indicating a need for careful monitoring.. These signals are derived from patterns in FDA reports and should be discussed with a healthcare provider for personalized assessment.
Teriparatide can cause injection site reactions, and patients should be monitored for signs of hypercalcemia and other serious adverse events. Always inform your healthcare provider about all medications, supplements, and over-the-counter drugs you are taking before starting Teriparatide.
Patients should report any unusual symptoms to their healthcare provider immediately. Proper administration techniques should be followed to minimize injection site reactions.
Teriparatide has 227,333 adverse event reports on file with the FDA. Serious adverse events, such as falls and death, are reported but at a lower rate compared to non-serious events. The volume of reports for Teriparatide reflects both the drug's usage level and the vigilance of the reporting community.
The FDA continues to monitor teriparatide for safety, and updates will be provided as necessary based on ongoing reviews. For the most current regulatory information, check the FDA's drug labeling database or consult your pharmacist.
Explore other medications manufactured by Eli Lilly and Company and compare their safety profiles:
The following drugs share commonly reported adverse reactions with TERIPARATIDE:
Drugs related to TERIPARATIDE based on therapeutic use, drug class, or shared indications: